We collaborate with a larger number of public and private hospitals and research centers through a number of national and international collaborative projects. These include MD Anderson (USA), Mc Gill (Canada), Paris Hospitals (APHP: Necker, Beaujon); Institut Gustave Roussy (Paris); CLB (Lyon), Val d'Hebron (Spain),...
For the first time in the clinic, the WINTHER trial applied transcriptomics (RNA expression testing) to tailor precision medicine in oncology to a greater number of patients based on the increased expression of RNA in tumors compared to normal tissues.
“Assessing RNA is an important adjunct to DNA profiling for determining precision treatments. WINTHER rings in a new era for personalized medicine in oncology,” concluded Josep Tabernero, Vice-Chairman WIN Consortium, Director VHIO and President ESMO.